Realizing the potential of tissue-targeted RNA therapies
miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient.
Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.
miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.